The development of efficient strategies to deliver therapeutics to malignant brain tumors (glioma, GBM) is critically needed due to the poor clinical efficacy of currently available treatments. This proposal seeks to target glioma stem cells in order to cut off the source stream of glioma stem cell phenotypes of various developmental stages, thus establishing a blueprint for effective gene therapies for heterogeneous cancers such as malignant glioma.
|Effective start/end date||11/1/15 → 7/31/22|
- National Cancer Institute (5R35CA197725-07)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.